Monthly News Roundup - February 2017
FDA Approves Once-Daily Qtern Tablets for Adults with Type 2 Diabetes
The U.S. Food and Drug Administration (FDA) has cleared AstraZeneca’s Qtern (dapagliflozin and saxagliptin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor and dipeptidyl...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Food and Drug Administration (FDA) | Forxiga | Pharmaceuticals | SGLT2 Inhibitors